Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jerusalem Pharmaceutical CoXPAE:JPH -1.11%75 5-Year Yield-on-Cost % is 4.23 as of Sep. 04, 2026, which is 39% above its 10-year median of 3.04. GuruFocus rates XPAE:JPH with a GF Score™ of 75/100 and a GF Value™ of $2.47 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 508 Drug Manufacturers companies, Jerusalem Pharmaceutical Co ranks better than 67.52% on this metric.
The historical rank and industry rank for Jerusalem Pharmaceutical Co's 5-Year Yield-on-Cost % or its related term are showing as below:
XPAE:JPH'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.03 Med: 3.04 Max: 5.1
Current: 4.23
During the past 13 years, Jerusalem Pharmaceutical Co's highest Yield on Cost was 5.10. The lowest was 1.03. And the median was 3.04.
XPAE:JPH's 5-Year Yield-on-Cost % is ranked better than 67.52% of 508
companies
in the Drug Manufacturers industry
Industry Median: 2.305
vs XPAE:JPH: 4.23
Jerusalem Pharmaceutical Co (XPAE:JPH) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Jerusalem Pharmaceutical Co 5-Year Yield-on-Cost % Related Terms
XPAE:JPH vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jerusalem Pharmaceutical Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jerusalem Pharmaceutical Co 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jerusalem Pharmaceutical Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Jerusalem Pharmaceutical Co's 5-Year Yield-on-Cost % falls into.
Jerusalem Pharmaceutical Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Jerusalem Pharmaceutical Co (XPAE:JPH) has a 5-Year Yield-on-Cost % of 4.23 as of Sep. 04, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Jerusalem Pharmaceutical Co and its competitors. This is 39% above median its historical median of 3.04. Over the past decade, Jerusalem Pharmaceutical Co's 5-Year Yield-on-Cost % has ranged from 1.03 to 5.10. According to the industry distribution chart, Jerusalem Pharmaceutical Co ranks #165 out of 508 companies in the Drug Manufacturers industry, placing it in the top 32.5%.
Is Jerusalem Pharmaceutical Co's 5-Year Yield-on-Cost % too high?
Jerusalem Pharmaceutical Co's current 5-Year Yield-on-Cost % of 4.23 is 39% above median its 10-year median of 3.04. Over the past 10 years, this metric has ranged from a low of 1.03 to a high of 5.10. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.31. Jerusalem Pharmaceutical Co's value of 4.23 is 83.5% above this industry median. Based on the distribution chart, Jerusalem Pharmaceutical Co ranks #165 out of 508 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Jerusalem Pharmaceutical Co has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jerusalem Pharmaceutical Co's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jerusalem Pharmaceutical Co ranks #165 out of 508 companies for 5-Year Yield-on-Cost %. This puts Jerusalem Pharmaceutical Co in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.31. Jerusalem Pharmaceutical Co's value of 4.23 is 83.5% above this benchmark. Historically, Jerusalem Pharmaceutical Co's own 5-Year Yield-on-Cost % has ranged from 1.03 to 5.10 over the past decade. While the company's 10-year median is 3.04 vs. the industry median of 2.31, Jerusalem Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.31, based on 508 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jerusalem Pharmaceutical Co's current 5-Year Yield-on-Cost % of 4.23 is 83.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Jerusalem Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jerusalem Pharmaceutical Co's current 5-Year Yield-on-Cost % is 4.23, which is 39% above median its own 10-year median of 3.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jerusalem Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jerusalem Pharmaceutical Co (XPAE:JPH) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.47, compared to a current price of $3.55 — trading 43.7% above its estimated fair value. The current 5-Year Yield-on-Cost % is 4.23, which is 39% above median its 10-year median of 3.04 and 83.5% above the Drug Manufacturers industry median of 2.31. Jerusalem Pharmaceutical Co's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Jerusalem Pharmaceutical Co (XPAE:JPH), the current 5-Year Yield-on-Cost % is 4.23 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jerusalem Pharmaceutical Co (XPAE:JPH) Overvalued in 2026?
Based on GuruFocus' analysis, Jerusalem Pharmaceutical Co stock appears to be overvalued.
The current stock price of $3.55 is trading 43.7% above its estimated GF Value™ of $2.47.
GuruFocus considers Jerusalem Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for XPAE:JPH:
5-Year Yield-on-Cost %: 4.23 (39% above median its 10-year median of 3.04)
GF Value™: $2.47 vs. price of $3.55 (43.7% above fair value)
Industry Position: 83.5% above the Drug Manufacturers median (#165 of 508)
No single metric tells the full story. See the XPAE:JPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jerusalem Pharmaceutical Co is engaged in developing, manufacturing and marketing of human pharmaceuticals products. It also produces detergent, cosmetic, personal and home care products, veterinary and agricultural products. The company operates in Jordan, Algeria, the Middle East, and North Africa Region. Its product portfolio contains more than 300 pharmaceutical products in various dosage forms including tablets, capsules, sterile injectables, powders for suspensions, suspensions, syrups, powders, suppositories, ovules, creams, ointments, as well as ear and nose drops and solutions.
75GF Score
Get the complete analysis for XPAE:JPH
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAE:JPH has been successfully added to your 
